Exposure to antiepileptic drugs in utero and child development: a prospective population-based study

Gyri Veiby1, Anne K Daltveit, Synnve Schjølberg

  • 1Department of Clinical Medicine, Section for Neurology, University of Bergen, Bergen, Norway. gyri.veiby@hotmail.com

Epilepsia
|July 20, 2013
PubMed

Insights

Antiepileptic drug exposure during pregnancy is linked to developmental delays in children. This includes issues with motor skills, language, and social-emotional development, even without congenital malformations.

Area of Science:

  • Developmental Pediatrics
  • Neuroscience
  • Pharmacology

Background:

  • Antiepileptic drugs (AEDs) are known teratogens, but their impact on later child development is less understood.
  • Prenatal exposure to AEDs may pose risks to neurodevelopment beyond congenital malformations.
  • Assessing developmental outcomes in children exposed to AEDs is crucial for informed clinical practice.

Purpose of the Study:

  • To investigate the association between prenatal exposure to antiepileptic drugs and early child development.
  • To evaluate developmental outcomes at 18 and 36 months of age in children exposed to AEDs in utero.
  • To determine if specific AEDs are associated with particular developmental deficits.

Main Methods:

  • Prospective cohort study of 108,264 children in the Norwegian Mother and Child Cohort Study (1999-2008).
  • Maternal reports on child development (motor, language, social, autistic traits) at 18 and 36 months.
  • Logistic regression analysis estimated odds ratios (ORs) for adverse outcomes, adjusting for confounders.

Main Results:

  • Prenatal AED exposure was associated with increased risks of abnormal gross motor skills and autistic traits at 18 months.
  • At 36 months, exposed children showed higher risks for abnormal gross motor skills, sentence skills, and autistic traits.
  • Increased risk of congenital malformations was observed, but developmental risks persisted even after exclusion.

Conclusions:

  • Prenatal exposure to antiepileptic drugs is associated with adverse developmental outcomes in early childhood.
  • Specific AEDs like valproate, lamotrigine, and carbamazepine showed varied associations with developmental domains.
  • These findings highlight the importance of careful consideration of AED use during pregnancy.
Abstract

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...